Su et al. reported that elimination of HCV also reduced the incidence of oral cancer; in a nationwide population study, HCV-infected individuals had a significantly increased risk of both OLP and oral cancer compared to noninfected individuals and antiviral therapy with pegylated IFN (PegIFN) and RBV significantly reduced the risk of HCV-related oral cancer [46]. The gene discussed is IFNA1; the disease is lip and oral cavity carcinoma.